Oregon Health and Science University (OHSU) and the Southern Research Institute have patented compounds reported to be useful for the treatment of alphaviral infections.
Nanjing Zaiming Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTACs) compounds comprising of E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Shanghai Yidi Biotechnology Co. Ltd. has patented dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or PDE4D2 inhibitors reported to be useful for the treatment of autoimmune, metabolic diseases, neurological and inflammatory disorders.
The University of Kentucky has prepared and tested mithramycin oxime derivatives reported to be useful for the treatment of cancer and neurological disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented tricyclic compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors and thus reported to be useful for the treatment of gram-negative bacterial infections.
Gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of type 2 diabetes and obesity have been disclosed in a Pfizer Inc. patent.
Cyrus Therapeutics Inc. has designed molecular glue degraders comprising a cereblon (CRBN)-binding moiety acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers potentially useful for the treatment of cancer.
Dice Alpha Inc. has prepared and tested substituted 6-imidazopyridazine IL-17A modulators potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.
RSS